GlassScriptPhysician profile
Lawrence Potter
NPI 1306826722
$4,392.94
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $29.72 · 2021: $345 · 2022: $1,111 · 2023: $1,360 · 2024: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505 · Education: $67.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.57 |
| Education | $67.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $778.80 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $708.46 | 2022-2024 | Tezspire |
| Genzyme Corporation | $531.84 | 2019-2024 | |
| Genentech USA, INC. | $420.57 | 2022-2024 | Xolair |
| Glaxosmithkline, LLC. | $371.82 | 2019-2024 | Nucala |
| Csl Behring | $338.14 | 2021-2024 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $279.98 | 2021-2024 | Hyqvia, Takhzyro, Glassia |
| Regeneron Healthcare Solutions, INC. | $271.31 | 2022-2024 | Dupixent |
| Kaleo, INC. | $182.20 | 2020-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $136.75 | 2019-2023 | Airduo Digihaler |
| Grifols USA, LLC | $96.54 | 2022-2024 | Xembify |
| Optinose US, INC. | $51.70 | 2024 | |
| Mylan Specialty L.P. | $43.67 | 2020-2023 | Yupelri |
| Pfizer INC. | $25.46 | 2024 | |
| Merck Sharp & Dohme LLC | $24.11 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $21.53 | 2023 | Cutaquig |
| Pharming Healthcare, INC. | $20.51 | 2021 | |
| Hospira, INC. | $20.03 | 2021 | |
| Biocryst US Sales Co., LLC | $19.97 | 2023 | Orladeyo |
| Shire North American Group INC | $19.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.02 | 2021 | |
| Abbvie INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.